COMMUNIQUÉS West-GlobeNewswire

BioSig Technologies Chief Executive Officer Mr. Anthony Amato Issues the Following Letter to Shareholders

21/05/2024 - 17:10

Westport, CT, May 21, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or “Company"), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal [...]

Genmab Completes Acquisition of ProfoundBio

21/05/2024 - 17:06

Company Announcement Genmab has completed acquisition of ProfoundBio for USD 1.8 billion in cash Acquisition gives Genmab worldwide rights to three candidates in clinical development, including rinatabart sesutecan ( [...]

Mobile-health Network Solutions Revenue Rises Approximately 120% in the First Six Months of Fiscal 2024

21/05/2024 - 17:00

SINGAPORE, May 21, 2024 (GLOBE NEWSWIRE) -- Mobile-health Network Solutions (Nasdaq: MNDR) (“MaNaDr” or “the Company”), a leading Asia-Pacific telehealth provider, today announced that for the first six months of fiscal [...]

AssureCare Joins Forces with Health Plan Alliance to Enhance Healthcare Collaboration

21/05/2024 - 16:00

CINCINNATI, Ohio, May 21, 2024 (GLOBE NEWSWIRE) -- AssureCare, a leading healthcare technology and services company, proudly announces its support of the Health Plan Alliance, a prominent national organization dedicated [...]

Intrommune Therapeutics Presents Oral Mucosal Immunotherapy Updates at Leading Industry Events

21/05/2024 - 15:35

NEW YORK, May 21, 2024 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a biotechnology company committed to developing a patient-friendly treatment platform for people with peanut and other food allergies, is pleased [...]

Merit Medical Launches basixSKY™ Inflation Device

21/05/2024 - 15:25

Versatile analog device offers fast inflation and ease of use, streamlining patient care SOUTH JORDAN, Utah, May 21, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare [...]

GT Biopharma, Inc. Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

21/05/2024 - 15:15

BRISBANE, CALIFORNIA, May 21, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP) (the “Company”), today announced that it has entered into a definitive securities purchase agreements for the purchase and sale of [...]

Lyra Therapeutics Announces Cost-Cutting Measures to Preserve Capital

21/05/2024 - 15:14

WATERTOWN, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), today announced that it is advancing its goal to preserve capital by implementing a layoff of [...]

Molecure receives approval to initiate a Phase II clinical trial (KITE) for OATD-01 for the treatment of pulmonary sarcoidosis in selected countries of the European Union and Norway

21/05/2024 - 15:00

OATD-01 is a first-in-class chitotriosidase 1 (CHIT1) inhibitor with the potential to modify the course of disease in sarcoidosis and other interstitial lung diseases. Obtaining regulatory approvals in Denmark, France, [...]

Solera HALO™ Platform Expands Fertility and Women’s Healthcare Solution with Kindbody

21/05/2024 - 15:00

Kindbody fertility, family-building, and women’s healthcare services expand upon Solera’s existing women’s health offering – spanning the full lifecycle of women’s health needs PHOENIX, May 21, 2024 (GLOBE NEWSWIRE) -- [...]

Philips Foundation 2023 Annual Report: unlocking quality medical services for over 28 million people in underserved communities

21/05/2024 - 15:00

May 21, 2024 Progress towards Philips Foundation’s 2030 target of 100 million lives improved in underserved communities each year 17 new initiatives with strategic partners and 4 new investments in health tech [...]

NeurAxis to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024

21/05/2024 - 15:00

CARMEL, Ind., May 21, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and [...]

Leisure Care Creates More Connected Lives for Residents with Nationwide Rollout of Rendever

21/05/2024 - 15:00

The VR company and senior living operator are taking their four-year partnership to the next level with immersive virtual reality experiences for residents in dozens of Leisure Care communities BOSTON, May 21, 2024 ( [...]

FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHD

21/05/2024 - 15:00

Phase 3 Data Collected to Date Sufficient for Submission of New Drug Application CTx-1301 Could Benefit >60% of ADHD Patients Currently Using Immediate-Release Booster Doses Advancing Discussions with [...]

Alpha Tau to Present at the Jefferies Global Healthcare Conference

21/05/2024 - 14:45

JERUSALEM, May 21, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that [...]

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

21/05/2024 - 14:45

BOSTON and LONDON, May 21, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today [...]

GRI Bio Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (SLE)

21/05/2024 - 14:35

Data presented at the 14 th International Congress on Autoimmunity Encouraging preclinical data observed to date on par with OFEV ® (nintedanib), a leading tyrosine kinase inhibitor with 2025 projected sales of $5 [...]

Ketabon To Present Advancements In At-Home Ketamine Therapy For Treatment-Resistant Depression At American Society Of Clinical Psychopharmacology Annual Meeting

21/05/2024 - 14:30

Presentations Will Address Phase 2 Trial Success With Lead Asset KET01 And Comparative Study With Intranasal SPRAVATO® MUNICH, Germany, May 21, 2024 (GLOBE NEWSWIRE) -- Ketabon GmbH (“Ketabon” or “the Company”), a joint [...]

Positive Statistically Significant Phase 2 Clinical Trial Results of Biodexa’s Newly-licensed eRapa™ in Familial Adenomatous Polyposis (FAP) Scheduled for Presentation at the 2024 Digestive Disease Week Annual Meeting

21/05/2024 - 14:30

May 21, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Positive Statistically Significant Phase 2 Clinical Trial Results of Biodexa’s Newly-licensed eRapa™ in Familial Adenomatous Polyposis (FAP) [...]